|
|
News Breaks | | | | September 4, 2012 | | 08:06 EDT |  | RNN | Rexahn Pharmaceuticals provides update on goals for 2012
Rexahn Pharmaceuticals provided an update on its strategic business goals for 2012. "I am pleased to report that Rexahn is executing to plan in 2012. Our primary objective for this year is to significantly advance and build the value of our oncology program," said the company. "Led by our recent positive Phase IIa clinical study results of Archexin in pancreatic cancer, I am pleased to report that we are accomplishing this goal. We are moving into the second half of this year with positive momentum." Rexahn Strategic Goals Update included: reported positive top-line phase IIa clinical study results for Archexin; completed phase I human study of RX-3117; submitted investigational new drug application for First-in-Class p68 Helicase Inhibitor RX-5902; active pursuit of new partnerships. Rexahn is in continuing dialogue with a range of potential partners, including out-licensing or co-development of the company's promising oncology assets; continuing evaluation of options for building additional value in CNS program; and continue new CEO search. Rexahn continues its search for a CEO to succeed Chang Ahn. | |
|
News For RNN From The Last 14 Days Check below for free stories on RNN the last two weeks. |
|
|
| There are no results for RNN |
|
|
|
|
|
|
